Deep Track Capital Issues Letter To Dynavax Technologies Shareholders

Cites Evidence That the Company is Not Living Up to Its Potential, As Demonstrated By 26% Year-To-Date Share Price Decline, Underperformance Versus Benchmarks, Precipitous 11% Drop Post-First Quarter Earnings and Fresh 52-Week Low

Highlights Concerns About Dynavax's Apparent Contentment Regarding Heplisav's Slowing Market Growth Expressed on Recent Earnings Call

Believes Directors with Shareholder-Aligned Perspective, Vaccine Commercialization Expertise and Capital Allocation Experience are Essential to Critically Evaluate the Company's Strategy and Realize the Full Value of Heplisav

Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees